Every year on July 28, the world observes World Hepatitis Day, one of the World Health Organization’s official global health campaigns. The day unites governments, healthcare providers, laboratories, and diagnostic manufacturers in raising awareness about viral hepatitis and promoting early testing.
Although hepatitis is preventable, treatable, and in many cases curable, millions of people continue to live with undiagnosed infections.
Among them, Hepatitis C Virus (HCV) remains one of the leading causes of chronic liver disease worldwide.
Because most infected individuals experience few or no symptoms during the early stages, many cases remain undetected until irreversible liver damage has already occurred.
This is why expanding access to rapid, accurate, and affordable testing has become a global healthcare priority.
The Global Burden of Hepatitis C
According to the World Health Organization,
- Millions of people are living with chronic Hepatitis C infection.
- Many remain unaware of their infection.
- Untreated HCV can progress to liver cirrhosis and liver cancer.
- Early diagnosis dramatically improves treatment outcomes.
Today, direct-acting antiviral (DAA) therapies can cure more than 95% of HCV infections when diagnosed and treated appropriately.
However, successful treatment always begins with one critical step:
Early testing.
Why Many HCV Infections Go Undetected
One of the biggest challenges in controlling Hepatitis C is its “silent” nature.
Many infected individuals:
- Have no symptoms
- Feel healthy for years
- Continue unknowingly transmitting infection
- Miss the optimal treatment window
Routine testing therefore plays an essential role, especially among:
- Blood donors
- Healthcare workers
- Dialysis patients
- High-risk populations
- People with previous blood transfusions
- Injection drug users
- Pregnant women in specific clinical settings
Why Rapid Testing Matters
Traditional laboratory testing remains the gold standard.
However, laboratory-based testing often requires:
- sophisticated equipment
- trained technicians
- centralized laboratories
- longer turnaround time
Rapid diagnostic tests help bridge this gap by providing timely preliminary testing results that enable healthcare providers to make faster decisions.
This is particularly valuable for:
- Community testingcampaigns
- Rural healthcare facilities
- Emergency departments
- Blood banks
- Mobile clinics
- Humanitarian programs
- Resource-limited countries
Introducing the Newscen HCV Antibody Rapid Test
Designed for Professional testing
The Newscen HCV Antibody Rapid Test is designed for qualitative detection of antibodies against Hepatitis C Virus in:
- Venous Whole blood
- Fingerstick blood
- Serum
- Plasma
It is intended for professional use in medical institutions by trained healthcare personnel.
Key Product Advantages
Fast Results
Results available in approximately 30 minutes, supporting efficient clinical workflow.
Flexible Sample Types
Supports
✓ Venous Whole Blood
✓ Fingerstick Blood
✓ Serum
✓ Plasma
Excellent Clinical Performance
Clinical evaluation demonstrated:
Sensitivity
99.76%
Specificity
100%
Broad Genotype Coverage
Validated across multiple HCV genotypes, supporting use in diverse geographic regions.
Built-In Quality Control
Integrated control line ensures correct test performance and reliable interpretation.
Typical Testing Environments
The Newscen HCV Antibody Rapid Test is designed for professional use by trained healthcare personnel and can be used in appropriate medical testing environments, including:
- Hospitals
- Clinical laboratories
- Medical diagnostic laboratories
- Outpatient clinics
- Community healthcare centers
- Blood collection centers
- Physician offices
- Healthcare institutions
The test is intended for professional in vitro diagnostic use in accordance with the Instructions for Use (IFU).
Why Healthcare Professionals Choose Rapid HCV antibody testing offers
Rapid HCV antibody testing offers multiple benefits:
- Earlier identification of infected individuals
- Improved patient referral
- Reduced diagnostic delay
- Expanded testingcoverage
- Better healthcare efficiency
When combined with confirmatory molecular testing, rapid antibody testing forms an important part of modern HCV diagnosis pathways.
Supporting Earlier Hepatitis C Detection
The World Health Organization aims to eliminate viral hepatitis as a public health threat by 2030.
Achieving this goal requires:
- More awareness
- Wider testing
- Earlier diagnosis
- Accessible diagnostics
- Affordable testing
- Reliable manufacturing partners
Diagnostic innovation will continue to play a key role in helping countries achieve these targets.
Why Choose Newscen?
Newscen is committed to delivering reliable in vitro diagnostic solutions for infectious disease testing.
Our advantages include:
- CE-marked products
- GMP manufacturing
- Professional technical support
- Stable product quality
- International distribution experience
- Comprehensive infectious disease rapid test portfolio
Together We Can Eliminate Hepatitis
This World Hepatitis Day, every testing test represents an opportunity to identify infection earlier, initiate timely treatment, and reduce transmission.
By making high-quality rapid diagnostics more accessible, healthcare providers and diagnostic manufacturers can work together toward a future free from viral hepatitis.
Newscen remains committed to empowering healthcare professionals with dependable rapid diagnostic solutions that help protect lives around the world.
Contact Us
Looking for a professional HCV antibody rapid test for laboratory and clinical use?
Contact Newscen to learn more about our HCV Antibody Rapid Test and complete infectious disease diagnostic portfolio.
Email: export@newscen.com
